Treatment options after sorafenib failure in patients with hepatocellular carcinoma
Imane El Dika, Ghassan K. Abou-Alfa
Clin Mol Hepatol. 2017;23(4):273-279.   Published online 2017 Nov 20     DOI: https://doi.org/10.3350/cmh.2017.0108
Citations to this article as recorded by Crossref logo
Novel Albumin–Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization
Jung Hee Kim, Dong Hyun Sinn, Jeong-Hoon Lee, Dongho Hyun, Sung Ki Cho, Sung Wook Shin, Young Chang, Yoon Jun Kim, Jung-Hwan Yoon, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi
Digestive Diseases and Sciences.2018; 63(4): 1062.     CrossRef
LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363
Hai Huang, Jie Chen, Cheng-Ming Ding, Xin Jin, Ze-Ming Jia, Jian Peng
Journal of Cellular and Molecular Medicine.2018; 22(6): 3238.     CrossRef
Why develop photoactivated chemotherapy?
Sylvestre Bonnet
Dalton Transactions.2018; 47(31): 10330.     CrossRef